ESLOY 0MSFT 7.08META -0.85HLPR.TO -0.02VDY.TO 0.38VGG.TO -0.01BIP.UN.TO 0.8TOU.TO -0.5
Abbott Labs (ABT)

NYSE:ABT

Abbott Labs (ABT)

90.75
+2.92 (3.32%)
as of Jun 23, 2026, 5:46:44 pm Market Open.
355 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 23, 2026, 12:00 am

This summary was created by AI, based on 17 opinions in the last 12 months.

Abbott Labs (ABT) has faced a challenging year marked by a significant share price decline of approximately 30%. Analysts note that the company's ability to deliver on its earnings growth target is critical amid increasing competition and recent struggles. Despite these setbacks, several experts maintain a long-term bullish outlook on the company's growth potential, particularly after recent acquisitions that could enhance its position in the oncology space. While the stock is currently priced below its historical valuation, analysts remain cautious due to recent technical breakdowns in its stock chart and ongoing challenges. The company is expected to report quarterly results soon, prompting a wait-and-see approach from some investors, although there is optimism about future growth driven by a stable market for medical devices and diagnostics.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
Bristol-Myers Squibb, BMY
DON'T BUY

Abbott Labs(ABT)

Jul 08, 2011
He has a model price of $57.97, an 8% upside. Good company but he sees a lot of value elsewhere.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$53.33

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 24, 2011
Raised dividend 30+ years in a row. Is going to show 10% earnings growth over next 2-3 years. A good space. They got too cheap so there is an opportunity.
Photo of Barry SchwartzBarry SchwartzUnlock Rating
$53.33

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

May 03, 2011
All different types of health care services and products. 11 times this year’s earnings. Nice valuation and entry point here.
Photo of Barry SchwartzBarry Schwartz
Owned
Unlock Rating
$52.85

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

May 02, 2011
(A Top Pick April 26/10. Up 8.35%.) Have both generic and branded drug divisions. Making acquisitions to increase their emerging market exposure, which currently represent 25% of their revenues. Also has the number one share in the drug alluding stent business. Very strong nutritional business.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$52.59

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 27, 2011
Only a part of their business is in the pharma. Biggest drug is Humera for rheumatoid arthritis, which doesn’t go off patent until 2016. Also have a strong nutritional business. Earnings have grown every single year since 1991. Trades at about 11X earnings. Almost 4% dividend.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$52.18

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Mar 16, 2011
Likes it. Patent on Humera goes off in 2016. 20 years in a row they increased earnings per share. Reasonable multiple. They are not getting the benefit of the doubt for the good work they are doing internationally. The health care sector is out of favour. Steadily increase the dividend.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$46.71

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Abbott Labs(ABT)

Feb 02, 2011
Annual succession of increased earnings since 1992 but not getting credit for what they are doing. Trades at about 10X earnings. Health care has been a tough sector to be in. Be patient and let the sector come back into favour and let the street endorse what they are doing. Street is worried about expiration of their major drug Humera but that doesn’t expire until 2016.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$45.73

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

Dec 15, 2010
(A Top Pick Jan 13/10. Down 10.82%.) Very consistent grower and still likes.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$48.12

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Nov 23, 2010
Recently checked back. Well managed and in good financial shape.
Photo of Don ReedDon Reed
Owned
Unlock Rating
$46.95

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Abbott Labs(ABT)

Nov 19, 2010
Good entry point at the support level of around $46. If it corrects and holds at $46, that is pretty powerful. Crummy relative strength, which is a pretty good sign. Do a partial Buy at $46 and another at around $43 and a final one at $41.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
No
Unlock Rating
$47.40

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jul 26, 2010
Diversified healthcare in the US. Have a branded pharmaceutical business providing drugs for arthritis, cholesterol and prostate cancer. Also had a nutritional business providing babies formula and adults’ nutrition. Also have stents, which is doing quite well globally. Trading at about 10.5X forward earnings. About 3.6% yield and have increased dividends on a regular basis.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$49.24

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

May 27, 2010
The model price is $48.13, a 2% upside only. Fully priced.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$47.87

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 12, 2010
Have a little less than 50% of their business in pharmaceuticals. Their big drug is Humera for rheumatoid arthritis and doesn't come off patent until 2016. Also have about 20%-25% revenues from their nutritional business.
Photo of Gordon ReidGordon ReidUnlock Rating
$49.15

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Apr 26, 2010
Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$50.37

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 14, 2010
Great company with a great pipeline. Humira, a rheumatoid arthritis drug, is their major product is on patent until 2016. Have never had a down year in stock price since 1992.
Photo of Don LatoDon Lato
Owned
Unlock Rating
$52.31

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
Showing 196 to 210 of 221 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TRI.TO 6.34$114.84
ZTS 0.63$76.52
MSCI 0.1$580.95
NVDA -8.57$200.08
BAC 0.54$57.91

Today's Top Picks

ESLOY 0$96.36
MSFT 7.08$374.42
META -0.85$563
HLPR.TO -0.02$36.38
VDY.TO 0.38$76.2

Popular Articles

Latest Sell Signals

CLS.TO -34.12$499.31
MBGYY 0$12.93
PLTR -3.025$116.475
ATZ.TO -6.21$156.35
AC.TO 0.25$24.2

Most Recent Experts

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video